Search research articles
Contact Us
Filters
Showing results (61-70 of 98) with videos related to
Page
of 10
Sort By:
The New England Journal of Medicine
|
March 31, 2021
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
Ronan J Kelly, Jaffer A Ajani, Jaroslaw Kuzdzal, et al.
The New England Journal of Medicine
|
October 23, 2023
Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma
Michiel S van der Heijden, Guru Sonpavde, Thomas Powles, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 5, 2023
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes
Martin Reck, Tudor-Eliade Ciuleanu, Manuel Cobo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 24, 2021
First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1
Martin Reck, Tudor-Eliade Ciuleanu, Jong-Seok Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 2023
Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial
Daniel S W Tan, Enriqueta Felip, Gilberto de Castro, et al.
Journal for Immunotherapy of Cancer
|
February 12, 2024
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial
David P Carbone, Tudor-Eliade Ciuleanu, Michael Schenker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 21, 2024
First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial
Yelena Y Janjigian, Jaffer A Ajani, Markus Moehler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 8, 2021
Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451
Taofeek K Owonikoko, Keunchil Park, Ramaswamy Govindan, et al.
JAMA Oncology
|
April 6, 2023
Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical Trial
Kevin J Harrington, Robert L Ferris, Maura Gillison, et al.
Journal for Immunotherapy of Cancer
|
August 6, 2024
Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden
Michael Schenker, Mauricio Burotto, Martin Richardet, et al.
Page
of 10
Search research articles
Search
Showing results (61-70 of 98) with videos related to
Sort By:
Page
of 10
The New England Journal of Medicine
|
March 31, 2021
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
Ronan J Kelly, Jaffer A Ajani, Jaroslaw Kuzdzal, et al.
The New England Journal of Medicine
|
October 23, 2023
Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma
Michiel S van der Heijden, Guru Sonpavde, Thomas Powles, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 5, 2023
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes
Martin Reck, Tudor-Eliade Ciuleanu, Manuel Cobo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 24, 2021
First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1
Martin Reck, Tudor-Eliade Ciuleanu, Jong-Seok Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 2023
Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial
Daniel S W Tan, Enriqueta Felip, Gilberto de Castro, et al.
Journal for Immunotherapy of Cancer
|
February 12, 2024
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial
David P Carbone, Tudor-Eliade Ciuleanu, Michael Schenker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 21, 2024
First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial
Yelena Y Janjigian, Jaffer A Ajani, Markus Moehler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 8, 2021
Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451
Taofeek K Owonikoko, Keunchil Park, Ramaswamy Govindan, et al.
JAMA Oncology
|
April 6, 2023
Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical Trial
Kevin J Harrington, Robert L Ferris, Maura Gillison, et al.
Journal for Immunotherapy of Cancer
|
August 6, 2024
Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden
Michael Schenker, Mauricio Burotto, Martin Richardet, et al.
Page
of 10